Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study-Reference-Cited by-同舟云学术

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study

Published:2019-04 Issue: Volume:111 Page:59-67
ISSN:0022-3956
Container-title:Journal of Psychiatric Research
language:en
Short-container-title:Journal of Psychiatric Research

Author:

Greden John F.,Parikh Sagar V.,Rothschild Anthony J.^ORCID,Thase Michael E.^ORCID,Dunlop Boadie W.,DeBattista Charles,Conway Charles R.,Forester Brent P.,Mondimore Francis M.^ORCID,Shelton Richard C.,Macaluso Matthew,Li James^ORCID,Brown Krystal,Gilbert Alexa,Burns Lindsey,Jablonski Michael R.,Dechairo Bryan

Funder

Ontario Brain Institute

Canadian Institutes of Health Research

James and Ethel Flinn Foundation

Allergan

AssureRx

Janssen

National Institute of Mental Health

Takeda

Eli-Lilly

Pfizer

Assurex Health

Acadia

Agency for Healthcare Research and Quality

Alkermes

Avanir

Forest

Intracellular

Otsuka

Patient-Centered Outcomes Research Institute

Axsome

Assurex Health and Brain Resources

LivaNova

Bristol-Myers Squibb

Stanley Medical Research Institute

NeoSync Inc

National Institutes of Health

Rogers Family Foundation

Eli Lilly

Biogen

Acadia Pharmaceuticals

Alkermes, Inc

Avanir Pharmaceuticals

Cerecor, Inc

Genomind

Intracellular Therapies

Janssen Pharmaceutica

Otsuka Pharmaceuticals

Takeda Pharmaceuticals

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference35 articles.

1. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes;Altar;Pharmacogenomics J.,2015

2. APA releases guideline on treatment of patients with major depressive disorder;Armstrong;Am. Fam. Physician,2011

3. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools;Bousman;Pharmacogenomics J Epub ahead of print,2018

4. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility;Bradley;J. Psychiatr. Res.,2018

5. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting;Brown;Clin. Therapeut.,2017

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression;Journal of Affective Disorders;2024-03

2. A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study;Pharmaceuticals;2024-01-23

3. Pharmacogenomic diversity in psychiatry: Challenges and Opportunities in Africa;2024-01-17

4. AI-Driven Decision-Making Applications in Pharmaceutical Sciences;Advances in Media, Entertainment, and the Arts;2024-01-10

5. User Experiences of Pharmacogenomic Testing and Opinions among Psychiatry Patients;Journal of Personalized Medicine;2023-12-23